Daniel H. Schneiderman
CIK: 0001565536
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Pasithea Therapeutics Corp.
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- May 1, 2026KTTA
Pasithea Therapeutics Corp.
Award(A)DirectStock Option (right to buy)
1.1M shares- - Nov 28, 2025KTTA
Pasithea Therapeutics Corp.
Award(A)Direct26.7K shares at avg. $0.75$20K - Oct 24, 2025KTTA
Pasithea Therapeutics Corp.
Award(A)DirectStock Option (right to buy)
317.3K shares-
1-3 of 3 transactions
About Schneiderman Daniel H
Schneiderman Daniel H (SEC CIK 0001565536) files insider reports with the SEC as Chief Financial Officer of Pasithea Therapeutics Corp. (KTTA).
Signal8 holds 3 ownership filings by Schneiderman Daniel H, all Form 4s, filed between Oct 27, 2025 and May 5, 2026. Those filings report 3 transactions, from Oct 24, 2025 to May 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Schneiderman Daniel H's filings is in MIAMI BEACH, FL.
Recent filings by Schneiderman Daniel H
Other insiders filing for Pasithea Therapeutics Corp. (KTTA)
- Coastlands Capital LP, 10% Owner
- Marques Tiago, Chief Executive Officer
- STEINMAN LAWRENCE, Director
- Dumesnil Simon, Director
- Krishnan Kartik, Chief Medical Officer
- Leahy Emer, Director